These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 8380664)

  • 1. Revertants of poliovirus escape mutants: new insights into antigenic structures.
    Ketterlinus R; Wiegers K; Dernick R
    Virology; 1993 Feb; 192(2):525-33. PubMed ID: 8380664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mapping of type 1 poliovirus neutralization epitopes.
    Blondel B; Crainic R; Dufraisse G; Candréa A; Horaud F
    Dev Biol Stand; 1985; 60():337-42. PubMed ID: 2412917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of monoclonal antibodies for the identification of the antigenic site for poliovirus neutralization.
    Minor PD; Schild GC; Evans D; Ferguson M; Almond J
    Dev Biol Stand; 1984; 57():171-5. PubMed ID: 6084608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antigenic sites of poliovirus type 3 eliciting IgA monoclonal antibodies in orally immunized mice.
    Buttinelli G; Ruggeri FM; Marturano J; Novello F; Donati V; Fiore L
    Virology; 2001 Mar; 281(2):265-71. PubMed ID: 11277698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus.
    Gromowski GD; Barrett AD
    Virology; 2007 Sep; 366(2):349-60. PubMed ID: 17719070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A single amino acid change within antigenic domain II of the spike protein of bovine coronavirus confers resistance to virus neutralization.
    Yoo D; Deregt D
    Clin Diagn Lab Immunol; 2001 Mar; 8(2):297-302. PubMed ID: 11238212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of neutralization-escape mutants selected from a mouse virulent type 1/type 2 chimeric poliovirus: identification of a type 1 poliovirus with antigenic site 1 deleted.
    Couderc T; Martin A; Wychowski C; Girard M; Horaud F; Crainic R
    J Gen Virol; 1991 Apr; 72 ( Pt 4)():973-7. PubMed ID: 1707949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence for a complex structure of neutralization antigenic site I of poliovirus type 1 Mahoney.
    Wiegers K; Uhlig H; Dernick R
    J Virol; 1988 May; 62(5):1845-8. PubMed ID: 2451760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antigenic modification of attenuated Sabin type 1 poliovirus by in vitro passages at supraoptimal temperatures.
    Crainic R; Blondel B; Candréa A; Dufraisse G; Horaud F
    Dev Biol Stand; 1985; 60():343-7. PubMed ID: 2995173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies of the antigenic variation in poliovirus type 1. Selection and analysis of variant strains with monoclonal antibodies by neutralization.
    Thibodeau L; Lacroix M; Lecomte J; Fauvel M
    Dev Biol Stand; 1984; 57():157-63. PubMed ID: 6084606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Production and characterization of murine IgA monoclonal antibodies to the surface antigens of rhesus rotavirus.
    Giammarioli AM; Mackow ER; Fiore L; Greenberg HB; Ruggeri FM
    Virology; 1996 Nov; 225(1):97-110. PubMed ID: 8918537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antigenic variation among 173 strains of type 3 poliovirus isolated in Finland during the 1984 to 1985 outbreak.
    Huovilainen A; Kinnunen L; Ferguson M; Hovi T
    J Gen Virol; 1988 Aug; 69 ( Pt 8)():1941-8. PubMed ID: 2841408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antigen chimaeras of poliovirus as potential new vaccines.
    Burke KL; Dunn G; Ferguson M; Minor PD; Almond JW
    Nature; 1988 Mar; 332(6159):81-2. PubMed ID: 2450279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolution of poliovirus during an outbreak: sequential type 3 poliovirus isolates from several persons show shifts of neutralization determinants.
    Huovilainen A; Hovi T; Kinnunen L; Takkinen K; Ferguson M; Minor P
    J Gen Virol; 1987 May; 68 ( Pt 5)():1373-8. PubMed ID: 2437244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid molecular evolution of wild type 3 poliovirus during infection in individual hosts.
    Kinnunen L; Huovilainen A; Pöyry T; Hovi T
    J Gen Virol; 1990 Feb; 71 ( Pt 2)():317-24. PubMed ID: 2155286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Principal and subsidiary antigenic sites of VP1 involved in the neutralization of poliovirus type 3.
    Minor PD; Evans DM; Ferguson M; Schild GC; Westrop G; Almond JW
    J Gen Virol; 1985 May; 66 ( Pt 5)():1159-65. PubMed ID: 2582084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutational analysis of a neutralization epitope on the dengue type 2 virus (DEN2) envelope protein: monoclonal antibody resistant DEN2/DEN4 chimeras exhibit reduced mouse neurovirulence.
    Hiramatsu K; Tadano M; Men R; Lai CJ
    Virology; 1996 Oct; 224(2):437-45. PubMed ID: 8874504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Canyon rim residues, including antigenic determinants, modulate serotype-specific binding of polioviruses to mutants of the poliovirus receptor.
    Harber J; Bernhardt G; Lu HH; Sgro JY; Wimmer E
    Virology; 1995 Dec; 214(2):559-70. PubMed ID: 8553558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutations conferring resistance to neutralization with monoclonal antibodies in type 1 poliovirus can be located outside or inside the antibody-binding site.
    Blondel B; Crainic R; Fichot O; Dufraisse G; Candrea A; Diamond D; Girard M; Horaud F
    J Virol; 1986 Jan; 57(1):81-90. PubMed ID: 2416957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antigenic structure of polioviruses of serotypes 1, 2 and 3.
    Minor PD; Ferguson M; Evans DM; Almond JW; Icenogle JP
    J Gen Virol; 1986 Jul; 67 ( Pt 7)():1283-91. PubMed ID: 2425046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.